Proton Re-Irradiation for Esophageal Cancer: A Single-Institution Retrospective Series von Bakhtiar, M., Wo, J.Y., Roberts, H.J., Parikh, A.R., Klempner, S.J., Clark, J.W., Strickland, M.R., Morse, C.R., Niemierko, A., Hong, T.S.

Volltext

Monitoring resistance through liquid biopsy von Parikh, A.R., Corcoran, R.B.

Volltext

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer von Berchuck, J.E., Facchinetti, F., DiToro, D.F., Baiev, I., Majeed, U., Reyes, S., Chen, C., Zhang, K., Sharman, R., Uson Junior, P.L.S., Maurer, J., Shroff, R.T., Pritchard, C.C., Wu, M.-J., Catenacci, D.V.T., Javle, M., Friboulet, L., Hollebecque, A., Bardeesy, N., Zhu, A.X., Lennerz, J.K., Tan, B., Borad, M., Parikh, A.R., Kiedrowski, L.A., Kelley, R.K., Mody, K., Juric, D., Goyal, L.

Volltext

97P Pan-cancer landscape of clonal tumor mutational burden (cTMB) von Parikh, A.R., Murugesan, K., Hopkins, J.F., Arshad, Z., Jin, D.X., Klempner, S.J., Fabrizio, D.A., Frampton, G.M., He, J., Montesion, M.

Volltext

Long-Term Outcomes of Definitive Chemoradiation with Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials von Lee, G., Nelson, B., Koenig, J.L., Plastaras, J.P., Metz, J.M., Yeap, B.Y., Drapek, L.C., Baglini, C., Ryan, D.P., Parikh, A.R., Allen, J.N., Clark, J.W., Blaszkowsky, L.S., Ben-Josef, E., Hong, T.S., Kharofa, J.R., Wo, J.Y.

Volltext

100P Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma von Necchi, A., Murugesan, K., Burn, T., Gjoerup, O., Greenstein, R., López, J.A., Montesion, M., Nimeiri, H., Parikh, A.R., Roychowdhury, S., Schwemmers, S., Silverman, I.M., Vogel, A.

Volltext

Association between Liver Metastases and Treatment Response in Patients with Metastatic, Microsatellite Stable Colorectal Cancer Treated with Radiation Therapy and Dual Immune Chec... von Koenig, J.L., Pappas, L., Yeap, B.Y., Clark, J.W., Allen, J.N., Wo, J.Y., Ryan, D.P., Blaszkowsky, L.S., Giantonio, B., Weekes, C., Klempner, S., Roberts, H.J., Drapek, L.C., Ly, L., Meurer, J., Corcoran, R., Mehta, A., Ting, D., Hong, T.S., Parikh, A.R.

Volltext

Synthesis, antitubercular evaluation and 3D-QSAR study of N-phenyl-3-(4-fluorophenyl)-4-substituted pyrazole derivatives von Khunt, R.C., Khedkar, V.M., Chawda, R.S., Chauhan, N.A., Parikh, A.R., Coutinho, E.C.

Volltext

Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor von Janku, F., Sherman, E.J., Parikh, A.R., Feun, L.G., Tsai, F., Allen, E., Zhang, C., Severson, P., Inokuchi, K., Walling, J., Averbuch, S., Tarcic, G., Bollag, G.

Volltext

Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations von Murugesan, K., Necchi, A., Burn, T.C., Gjoerup, O., Greenstein, R., Krook, M., López, J.A., Montesion, M., Nimeiri, H., Parikh, A.R., Roychowdhury, S., Schwemmers, S., Silverman, I.M., Vogel, A.

Volltext

Mutational landscape of metastatic cancers discovered from prospective clinical sequencing at community practice cancer program von Alvarez, R.H., Moran, A., Meiri, E., Loaiza-Bonilla, A., Parikh, A.R., Crilley, P., Elvin, J., Reddy, P., Miller, V.A., Zook, S., Ali, S.M., Markman, M.

Volltext

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours von Corcoran, R.B., Do, K.T., Cleary, J.M., Parikh, A.R., Yeku, O.O., Weekes, C.D., Veneris, J., Ahronian, L.G., Mauri, G., Van Seventer, E.E., Fetter, I.J., Gurski, J.M., Matulonis, U.A., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J.W., Heist, R.S., Shapiro, G.I.

Volltext

447PD - Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours von Corcoran, R.B., Do, K.T., Cleary, J.M., Parikh, A.R., Yeku, O.O., Weekes, C.D., Veneris, J., Ahronian, L.G., Mauri, G., Van Seventer, E.E., Fetter, I.J., Gurski, J.M., Matulonis, U.A., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J.W., Heist, R.S., Shapiro, G.I.

Volltext

Synthesis and characterization of barbitones as antimicrobial agents von Sangani H.G., Bhimani K.B., Khunt R.C., Parikh A.R.

Volltext

Synthesis and characterization of barbitones as antimicrobial agents von Sangani, H.G., Bhimani, K.B., Khunt, R.C., Parikh, A.R.

Volltext

Management of Infected Amputation Sites Following Failed Prosthetic Bypass Grafts von Parikh, A.R., Wijesinghe, L.D., Kent, P.J., Scott, D.J.A.

Volltext

Testability analysis of multichip systems von Abadir, M.S., Parikh, A.R.

Volltext bestellen

Analyzing multichip module testing strategies von Abadir, M.S., Parikh, A.R., Sandborn, P.A., Drake, K., Bal, L.

Volltext

P3.13D.01 Proteomic Characterization of Antibody Drug Conjugate Target Expression Profiles in Small Cell Lung Cancer (SCLC) von Lin, E., Khosla, A., Smrecek, N.K., Naqash, A.R., Parikh, K., Boumber, Y., Khalil, M., Desai, A.

Volltext

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors von Cortes, J., Digumarti, R., Parikh, P.M., Wetzler, M., Lipton, J.H., Hochhaus, A., Craig, A.R., Benichou, A.‐C., Nicolini, F.E., Kantarjian, H.M.

Volltext